CN111808190B - 结合pd-1的抗体 - Google Patents

结合pd-1的抗体 Download PDF

Info

Publication number
CN111808190B
CN111808190B CN202010275368.4A CN202010275368A CN111808190B CN 111808190 B CN111808190 B CN 111808190B CN 202010275368 A CN202010275368 A CN 202010275368A CN 111808190 B CN111808190 B CN 111808190B
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
ser
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010275368.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111808190A (zh
Inventor
岳海涛
林键
裴树军
梁世忠
李胜峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Thera Solutions Ltd
Original Assignee
Bio Thera Solutions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Thera Solutions Ltd filed Critical Bio Thera Solutions Ltd
Priority to CN202311534081.9A priority Critical patent/CN117603355A/zh
Publication of CN111808190A publication Critical patent/CN111808190A/zh
Application granted granted Critical
Publication of CN111808190B publication Critical patent/CN111808190B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202010275368.4A 2019-04-10 2020-04-09 结合pd-1的抗体 Active CN111808190B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311534081.9A CN117603355A (zh) 2019-04-10 2020-04-09 结合pd-1的抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910286677 2019-04-10
CN2019102866779 2019-04-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311534081.9A Division CN117603355A (zh) 2019-04-10 2020-04-09 结合pd-1的抗体

Publications (2)

Publication Number Publication Date
CN111808190A CN111808190A (zh) 2020-10-23
CN111808190B true CN111808190B (zh) 2023-12-12

Family

ID=72750942

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010275368.4A Active CN111808190B (zh) 2019-04-10 2020-04-09 结合pd-1的抗体
CN202311534081.9A Pending CN117603355A (zh) 2019-04-10 2020-04-09 结合pd-1的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311534081.9A Pending CN117603355A (zh) 2019-04-10 2020-04-09 结合pd-1的抗体

Country Status (6)

Country Link
US (1) US12466887B2 (enExample)
EP (1) EP3931223A4 (enExample)
JP (1) JP7641910B2 (enExample)
CN (2) CN111808190B (enExample)
AR (1) AR118619A1 (enExample)
WO (1) WO2020207432A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115776898A (zh) * 2020-07-07 2023-03-10 百奥泰生物制药股份有限公司 双特异性抗体及其应用
CN121668303A (zh) * 2020-10-11 2026-03-17 百奥泰生物制药股份有限公司 抗pd-1抗体在联合用药中的应用
WO2025140324A1 (zh) * 2023-12-26 2025-07-03 百奥泰生物制药股份有限公司 抗pd-1抗体联合化疗剂在治疗肿瘤中的用途
WO2025190251A1 (zh) * 2024-03-12 2025-09-18 百奥泰生物制药股份有限公司 抗trop2抗体药物偶联物和pd-1拮抗剂联合治疗实体瘤的用途
CN120919340A (zh) * 2024-05-09 2025-11-11 百奥泰生物制药股份有限公司 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用
CN121015902A (zh) * 2024-05-27 2025-11-28 百奥泰生物制药股份有限公司 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途
CN121754666A (zh) * 2024-09-30 2026-03-31 百奥泰生物制药股份有限公司 一种抗pd-1抗体制剂及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018181064A1 (ja) * 2017-03-27 2018-10-04 国立大学法人北海道大学 Ｐｄ－ｌ１検出用抗ｐｄ－ｌ１抗体
WO2018217227A1 (en) * 2017-05-24 2018-11-29 Immunomedics, Inc. Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
CN108997499A (zh) * 2018-09-12 2018-12-14 首都医科大学附属北京胸科医院 一种抗人pd-l1抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
KR101586617B1 (ko) * 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
AU2016333517B2 (en) 2015-10-02 2023-09-07 Les Laboratoires Servier Anti-PD-1 antibodies and compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018181064A1 (ja) * 2017-03-27 2018-10-04 国立大学法人北海道大学 Ｐｄ－ｌ１検出用抗ｐｄ－ｌ１抗体
WO2018217227A1 (en) * 2017-05-24 2018-11-29 Immunomedics, Inc. Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
CN108997499A (zh) * 2018-09-12 2018-12-14 首都医科大学附属北京胸科医院 一种抗人pd-l1抗体及其应用

Also Published As

Publication number Publication date
AR118619A1 (es) 2021-10-20
US12466887B2 (en) 2025-11-11
EP3931223A1 (en) 2022-01-05
JP2022538375A (ja) 2022-09-02
US20220204623A1 (en) 2022-06-30
CN111808190A (zh) 2020-10-23
WO2020207432A1 (en) 2020-10-15
JP7641910B2 (ja) 2025-03-07
CN117603355A (zh) 2024-02-27
EP3931223A4 (en) 2023-07-12
TW202104262A (zh) 2021-02-01

Similar Documents

Publication Publication Date Title
TWI754800B (zh) 新型抗ox40/pd-l1雙特異性抗體分子、新型抗vegf/gitr雙特異性抗體分子及其用途
US11555077B2 (en) 4-1BB antibody and preparation method and use thereof
CN110407941B (zh) Cd39的高亲和力抗体及其用途
JP7641910B2 (ja) Ｐｄ－１と結合する抗体
BR112021010402A2 (pt) Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos
WO2018205985A1 (zh) 含有TGF-β受体的融合蛋白及其医药用途
ME02093B (me) Antitijela za humani receptor programirane smrti pd-1
CN108463472A (zh) 具有修饰的j-链的结合分子
AU2019218319A1 (en) Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
TW202216768A (zh) Ｌａｉｒ－１結合劑及其使用方法
US20230183342A1 (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
CA3203257A1 (en) Anti-b7-h3 antibody and uses thereof
JP2024534795A (ja) 二重特異性抗体およびその使用
EP4671280A1 (en) ANTI-NECTIN-4 ANTIBODY AND MULTISPECIFIC ANTIBODY CONTAINER
WO2023045370A1 (zh) 靶向tigit的单克隆抗体
WO2023052541A1 (en) Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
TWI916327B (zh) 結合pd-1的抗體
CN120230216B (zh) 抗lair1抗体及其用途
HK40033623A (en) Antibody binding to pd-1
HK40033623B (zh) 结合pd-1的抗体
RU2776204C1 (ru) Слитый белок, содержащий рецептор tgf-бета, и его фармацевтическое применение
JP2024536716A (ja) ＰＤ－Ｌ１、ＣＤ１３７及び／又はＴＧＦβへの二重特異性及び三重特異性結合タンパク質ならびにそれらの使用
WO2024193668A1 (zh) 抗ctla-4/抗tigit双特异性抗体及其应用
KR20230169942A (ko) 항-pd-l1 항체 및 이의 용도
HK40112413A (zh) 与PD-L1、CD137和/或TGFβ的双特异性和三特异性结合蛋白及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40033623

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant